Affordable HPV Vaccination
On June 29, 2006, the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimously recommended Merck’s new Human Papillomavirus vaccine, GARDASIL®, for girls and women 11 to 26 years old. The Committee also approved the vaccine for 9- and 10-year-old girls at the discretion of their physicians.
The GARDASIL vaccine is the only vaccine available in the United States for the prevention of HPV types 16- and 18- related cervical cancer. GARDASIL is to be administered in three separate doses over a six-month period. Each dose of GARDASIL currently sells for $120, putting a price tag of $360 on the full HPV vaccination. Merck has, however, been working hard to try to distribute the vaccine to those who cannot afford it, both within the U.S. and abroad.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
